CAI International, Inc. Q2 2026 Earnings Recap

Caris Life Sciences shares surged 24.2% following Q2 results as strong case volume growth and early enthusiasm for the Caris Detect multi-cancer early detection (MCED) test significantly exceeded investor expectations.

Key Takeaways

• Total cases reached a record 59,200 in Q2, representing an 18% year-over-year increase, driven by both tissue and blood testing volumes.
• Over 345,000 clinical oncology tests were performed, including more than 114,000 Whole Exome and Whole Transcriptome tests.
• The proprietary database grew to over 1.13 million profiled patients, supporting Caris' AI-driven comprehensive molecular oncology platform.
• Caris Detect MCED test drew physician and patient interest surpassing management’s own forecasts, with near-term demand potentially outpacing rollout capacity.
• Expansion of the Precision Oncology Alliance added key members, strengthening commercial reach and collaborative research.